Group items tagged

The Medical Product Safety Network (MedSun) improves FDA's understanding of problems with the use of medical devices so that the FDA, healthcare facilities, clinicians, and manufacturers can better address safety concerns. The MedSun Web page is a newsletter-based website which provides monthly updates about timely medical device issues that may impact patient safety. This website also provides public access to de-identified reports 2 sent into the MedSun program, in addition to important safety information to MedSun participants and to the national clinical community about reported problems.

MedWatch - FDA Safety Information and Adverse Event Report Program - MedWatch alerts provide timely new safety information on human drugs, medical devices, vaccines and other biologics, dietary supplements, and cosmetics. The alerts contain actionable information that may impact both treatment and diagnostic choices for healthcare professional and patient.

Study to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.

National Council on Patient Information and Education NCPIE - One of the original patient safety coalitions, MCPIE works to advance the safe, appropriate use of medicines through enhanced communication

FDA is an agency within the Department of Health and Human Services1 and consists of centers and offices responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation.

Builds safety beds for special needs children, youth and adults as well as handicapped, disabled and medically fragile individuals who need extra fall and entrapment protection while in bed.

Information on ongoing study being sponsored by Medical College of Georgia to test the safety and effectiveness of cord blood infusion in children with motor disabilities due to cerebral palsy.

Safety and Efficacy of Vanquix™ Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory Patients With Epilepsy Who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures

Study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.

Hypothesis of study is that among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm delivery.This study involves two concurrent double-blinded randomized clinical trials of 17OHP versus placebo. Each trial will test the efficacy and safety of 17OHP in women with a specific risk factor for preterm birth. The two risk factors to be studied are: Twin pregnancy - Triplet pregnancy

Study being sponsored by the Medical College of Georgia to test the safety and effectiveness of a cord blood infusion in children who have motor disability due to cerebral palsy (CP).

To evaluate the safety and efficacy of magnesium sulfate for preterm suspected abruption

Effect of treatment on the movement disorder will be measured by a myoclonus scale and a dystonia scale as well as by assessment of overall functional status. Response at various dosages will be compared to baseline for all patients.Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication.